Daré Bioscience, Inc.
DARE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.17 | 0.05 | 0.10 |
| FCF Yield | 18.19% | -137.41% | -25.86% | -23.53% |
| EV / EBITDA | -0.52 | -0.64 | -1.15 | -1.82 |
| Quality | ||||
| ROIC | -2,253.31% | -2,435.24% | -249.07% | -97.61% |
| Gross Margin | -146,110.22% | -670.62% | -201.42% | 0.00% |
| Cash Conversion Ratio | -1.33 | 1.29 | 0.58 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -90.07% | – | – | – |
| Free Cash Flow Growth | 112.21% | -117.54% | 36.93% | -13.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.61 | 0.30 | 1.09 | 1.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 8,542.52 | 66.28 | 37.61 | -7,676.25 |